Minko T

No ORCID on file · 2 papers in corpus · active 2023-2024
2024
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.
Cancer cell international ·doi:10.1186/s12935-024-03469-0

BackgroundOlaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grad…

2023
Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.
Pharmaceutical research ·doi:10.1007/s11095-022-03434-4

Anticancer vaccines represent a promising approach for effective treatment of cancer and along with recent advantages of nucleic acid-based vaccines for other diseases form a prospective and potentially efficacious direction of the research…